|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||369.00 - 380.60|
|52-week range||308.57 - 390.01|
|Beta (5Y monthly)||0.25|
|PE ratio (TTM)||20.90|
|Forward dividend & yield||9.78 (2.64%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||N/A|
J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.
Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.
Basel, 22 July 2021 Group sales up 8%1 at constant exchange rates (CER); 5% in Swiss francsPharmaceuticals Division sales decline 3%; sales grow 4% in the second quarter, following a first-quarter decrease of 9%; newly launched medicines (+30%) compensate for the continued impact from biosimilarsDiagnostics Division sales grow 51% due to high demand for COVID-19 tests and strong momentum in routine testingIFRS net income increases by 2% (-3% in Swiss francs), while core earnings per share up 6%H